+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pegfilgrastim Biosimilars Global Market Report 2021: COVID-19 Growth and Change to 2030

  • ID: 5446203
  • Report
  • September 2021
  • Region: Global
  • 175 Pages
  • The Business Research Company

FEATURED COMPANIES

  • Biocon
  • Coherus
  • Fresenius Kabi
  • Intas Pharmaceuticals
  • Mundipharma
  • Mylan
Pegfilgrastim Biosimilars Global Market Report 2021: COVID-19 Growth and Change to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global pegfilgrastim biosimilars market.







This report focuses on the pegfilgrastim biosimilars market which is experiencing strong growth. The report gives a guide to the pegfilgrastim biosimilars market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for pegfilgrastim biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Pegfilgrastim Biosimilars market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider pegfilgrastim biosimilars market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The pegfilgrastim biosimilars market section of the report gives context. It compares the pegfilgrastim biosimilars market with other segments of the pegfilgrastim biosimilars market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, pegfilgrastim biosimilars indicators comparison.

Scope


Markets Covered:


  • By Application: Chemotherapy Treatment; Transplantation; Others
  • By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Mail-Order Pharmacies

Companies Mentioned:


Mylan; Biocon; Mundipharma; Pfizer; Sandoz

Countries:


Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions:


Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series:


Five years historic and ten years forecast.

Data:


Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data segmentations:


Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing:


Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Pegfilgrastim Biosimilars Market

What is the estimated value of the Global Pegfilgrastim Biosimilars Market?

The Global Pegfilgrastim Biosimilars Market was estimated to be valued at $0.9 billion in 2021.

What is the growth rate of the Global Pegfilgrastim Biosimilars Market?

The growth rate of the Global Pegfilgrastim Biosimilars Market is 12.7%, with an estimated value of $1.4 billion by 2025.

What is the forecasted size of the Global Pegfilgrastim Biosimilars Market?

The Global Pegfilgrastim Biosimilars Market is estimated to be worth $1.4 billion by 2025.

Who are the key companies in the Global Pegfilgrastim Biosimilars Market?

Key companies in the Global Pegfilgrastim Biosimilars Market include Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus and Fresenius Kabi.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Biocon
  • Coherus
  • Fresenius Kabi
  • Intas Pharmaceuticals
  • Mundipharma
  • Mylan
1. Executive Summary

2. Pegfilgrastim Biosimilars Market Characteristics

3. Pegfilgrastim Biosimilars Market Trends and Strategies

4. Impact Of COVID-19 On Pegfilgrastim Biosimilars

5. Pegfilgrastim Biosimilars Market Size and Growth
5.1. Global Pegfilgrastim Biosimilars Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Pegfilgrastim Biosimilars Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market

6. Pegfilgrastim Biosimilars Market Segmentation
6.1. Global Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Chemotherapy Treatment
  • Transplantation
  • Others
6.2. Global Pegfilgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital pharmacies
  • Retail pharmacies
  • Mail-Order pharmacies

7. Pegfilgrastim Biosimilars Market Regional and Country Analysis
7.1. Global Pegfilgrastim Biosimilars Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Pegfilgrastim Biosimilars Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Pegfilgrastim Biosimilars Market
8.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Pegfilgrastim Biosimilars Market
9.1. China Pegfilgrastim Biosimilars Market Overview
9.2. China Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Pegfilgrastim Biosimilars Market
10.1. India Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Pegfilgrastim Biosimilars Market
11.1. Japan Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Pegfilgrastim Biosimilars Market
12.1. Australia Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Pegfilgrastim Biosimilars Market
13.1. Indonesia Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Pegfilgrastim Biosimilars Market
14.1. South Korea Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Pegfilgrastim Biosimilars Market
15.1. Western Europe Pegfilgrastim Biosimilars Market Overview
15.2. Western Europe Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Pegfilgrastim Biosimilars Market
16.1. UK Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Pegfilgrastim Biosimilars Market
17.1. Germany Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Pegfilgrastim Biosimilars Market
18.3. France Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Pegfilgrastim Biosimilars Market
19.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview
19.2. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Pegfilgrastim Biosimilars Market
20.1. Russia Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Pegfilgrastim Biosimilars Market
21.1. North America Pegfilgrastim Biosimilars Market Overview
21.2. North America Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Pegfilgrastim Biosimilars Market
22.1. USA Pegfilgrastim Biosimilars Market Overview
22.2. USA Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Pegfilgrastim Biosimilars Market
23.1. South America Pegfilgrastim Biosimilars Market Overview
23.2. South America Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Pegfilgrastim Biosimilars Market
24.1. Brazil Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Pegfilgrastim Biosimilars Market
25.1. Middle East Pegfilgrastim Biosimilars Market Overview
25.2. Middle East Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Pegfilgrastim Biosimilars Market
26.1. Africa Pegfilgrastim Biosimilars Market Overview
26.2. Africa Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Pegfilgrastim Biosimilars Market Competitive Landscape and Company Profiles
27.1. Pegfilgrastim Biosimilars Market Competitive Landscape
27.2. Pegfilgrastim Biosimilars Market Company Profiles
27.2.1. Mylan
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Biocon
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Mundipharma
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Pfizer
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Sandoz
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. Pegfilgrastim Biosimilars Pipeline Analysis

29. Key Mergers and Acquisitions in the Pegfilgrastim Biosimilars Market

30. Pegfilgrastim Biosimilars Market Future Outlook and Potential Analysis

31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Biocon
  • Coherus
  • Fresenius Kabi
  • Intas Pharmaceuticals
  • Mundipharma
  • Mylan
Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals, and Fresenius Kabi.

The global pegfilgrastim biosimilars market is expected to grow from $0.8 billion in 2020 to $0.88 billion in 2021 at a compound annual growth rate (CAGR) of 10%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.42 billion in 2025 at a CAGR of 13%.

The pegfilgrastim biosimilars market consists of the sales of pegfilgrastim biosimilars and related services offered by the companies that develop and manufacture them. Pegfilgrastim is a version of filgrastim (Neupogen), used to increase the production of infection-fighting white blood cells for the treatment of cancer patients undergoing chemotherapy. Pegfilgrastim biosimilars find their applications in reducing infection for patients undergoing anticancer therapy.

The pegfilgrastim biosimilar market covered in this report is segmented by application into chemotherapy treatment, transplantation, others and by distribution channel into hospital pharmacies, retail pharmacies, mail-order pharmacies.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

During the historic period the pegfilgrastim biosimilar market was restrained by the low number of drug approvals by the FDA. The market currently only has 4 drugs approved for treatment, thus restraining the growth of the market. This can be attributed to strict standards for manufacturing and high drug efficacy standards set by the regulatory bodies for approval of this therapy, thus increasing the time required for approval and limiting the growth of the market.

In October 2018, Mundipharma, a UK-based company engaged in manufacturing, developing, and commercializing high-quality biosimilars for inflammatory diseases and oncology acquired Cinfa Biotech. Mundipharma acquired all shares of Cinfa, Infarco including Pelmeg (pegfilgrastim, biosimilar). This acquisition is projected to expand Mundipharma's biosimilar product portfolio. Cinfa Biotech was founded in 2013 as a part of Cinfa Group and is a Spanish biotechnology company that focuses on the development of biosimilars.

Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars. Governments worldwide are focusing on the development of biosimilars attributing to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, in July 2018 to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative and in 2018 they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aids in the increased production and awareness which in turn supported the growth of the pegfilgrastim biosimilars market.

Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships, in or out licensing deals, this trend has been increasing over the recent years. For instance, in July 2018, Fulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved by the FDA.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Mylan
  • Biocon
  • Mundipharma
  • Pfizer
  • Sandoz
  • Coherus
  • Intas Pharmaceuticals
  • Fresenius Kabi
Note: Product cover images may vary from those shown

Loading
LOADING...